Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

Share this content:
Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors
Myocarditis Rare Side Effect of Immune Checkpoint Inhibitors

FRIDAY, April 6, 2018 (HealthDay News) -- Myocarditis in patients treated with immune checkpoint inhibitors (ICIs) may be more common than previously thought, according to a study published online March 19 in the Journal of the American College of Cardiology.

Syed S. Mahmood, M.D., M.P.H., from the New York-Presbyterian Hospital in New York City, and colleagues used data from an eight-site registry of 35 patients with ICI-associated myocarditis (November 2013 to July 2017). Medical records were used to understand the presentation and clinical course of ICI-associated myocarditis.

The researchers found that the prevalence of myocarditis was 1.14 percent, with a median time of onset of 34 days after starting ICIs. Case characteristics included an average age of 65 years, 29 percent female, and 54 percent had no other immune-related side effects. Combination ICI (P < 0.001) and diabetes (P = 0.01) were more common in cases, compared to controls. Major adverse cardiac events (MACE) developed in 46 percent of patients over 102 days of median follow-up. The risk of MACE was elevated four-fold with troponin T ≥1.5 ng/mL (hazard ratio 4.0; P = 0.003).

"Myocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Increase Seen in Salmonella Illnesses From Ground Beef

CDC: Increase Seen in <i>Salmonella</i> Illnesses From Ground ...

246 people now sickened; 59 people have been hospitalized; no deaths reported to date

Epinephrine Personal Autoinjectors Cost-Effective at 24

Epinephrine Personal Autoinjectors Cost-Effective at &#36;24

Based on 10-fold fatality risk difference, value-based price for personal epinephrine $24

Burden of Liver Cancer Rising in Medicare Patients

Burden of Liver Cancer Rising in Medicare Patients

Coexistence of other liver conditions tied to even higher risk for death, health care costs

is free, fast, and customized just for you!




Already a member?

Sign In Now »